Literature DB >> 24184921

Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia.

Pavan K Shetty1, Francesca Galeffi2, Dennis A Turner2.   

Abstract

Prolonged hypoxia leads to irreversible loss of neuronal function and metabolic impairment of nicotinamide adenine dinucleotide recycling (between NAD(+) and NADH) immediately after reoxygenation, resulting in NADH hyperoxidation. We test whether the addition of nicotinamide (to enhance NAD(+) levels) or PARP-1 inhibition (to prevent consumption of NAD(+)) can be effective in improving either loss of neuronal function or hyperoxidation following severe hypoxic injury in hippocampal slices. After severe, prolonged hypoxia (maintained for 3min after spreading depression) there was hyperoxidation of NADH following reoxygenation, an increased soluble NAD(+)/NADH ratio, loss of neuronal field excitatory post-synaptic potential (fEPSP) and decreased ATP content. Nicotinamide incubation (5mM) 2h prior to hypoxia significantly increased total NAD(H) content, improved neuronal recovery, enhanced ATP content, and prevented NADH hyperoxidation. The nicotinamide-induced increase in total soluble NAD(H) was more significant in the cytosolic compartment than within mitochondria. Prolonged incubation with PJ-34 (>1h) led to enhanced baseline NADH fluorescence prior to hypoxia, as well as improved neuronal recovery, NADH hyperoxidation and ATP content on recovery from severe hypoxia and reoxygenation. In this acute model of severe neuronal dysfunction prolonged incubation with either nicotinamide or PJ-34 prior to hypoxia improved recovery of neuronal function, enhanced NADH reduction and ATP content, but neither treatment restored function when administered during or after prolonged hypoxia and reoxygenation.
© 2013.

Entities:  

Keywords:  ACSF; AIF; Brain; CA1; DG; H; HSD; Hippocampus; Hypoxia; NAD(+); NAD(H); NAM; Nicotinamide; PARP-1; ROI; ROS; SIRT-1; SR; Spreading depression; TCA cycle; apoptosis-inducing factor; artificial cerebrospinal fluid; cornu ammonis region 1; dentate gyrus; fEPSP; field excitatory post-synaptic potential; hypoxia; hypoxic spreading depression; nicotinamide; nicotinamide adenine dinucleotide; poly(ADP-ribose) polymerase-1; reactive oxygen species; region of interest; reox; reoxygenation; silent mating-type information regulation 1; stratum radiatum; total NAD(+) and NADH content; tricarboxylic acid cycle

Mesh:

Substances:

Year:  2013        PMID: 24184921      PMCID: PMC4143422          DOI: 10.1016/j.nbd.2013.10.025

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  41 in total

1.  The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in Wistar rats.

Authors:  Jun Yang; Lori K Klaidman; Artak Nalbandian; Jasmine Oliver; Mei L Chang; Pak H Chan; James D Adams
Journal:  Neurosci Lett       Date:  2002-11-22       Impact factor: 3.046

2.  Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia.

Authors:  F Moroni; E Meli; F Peruginelli; A Chiarugi; A Cozzi; R Picca; P Romagnoli; R Pellicciari; D E Pellegrini-Giampietro
Journal:  Cell Death Differ       Date:  2001-09       Impact factor: 15.828

3.  A comparison of the effects of nicotinamide and progesterone on functional recovery of cognitive behavior following cortical contusion injury in the rat.

Authors:  Todd C Peterson; Gail D Anderson; Eric D Kantor; Michael R Hoane
Journal:  J Neurotrauma       Date:  2012-11-27       Impact factor: 5.269

4.  Effect of transient focal ischemia of mouse brain on energy state and NAD levels: no evidence that NAD depletion plays a major role in secondary disturbances of energy metabolism.

Authors:  W Paschen; L Oláh; G Mies
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

Review 5.  Medicinal chemistry of nicotinamide in the treatment of ischemia and reperfusion.

Authors:  J Yang; L K Klaidman; J D Adams
Journal:  Mini Rev Med Chem       Date:  2002-04       Impact factor: 3.862

Review 6.  NAD(P)H, a directly operating antioxidant?

Authors:  M Kirsch; H De Groot
Journal:  FASEB J       Date:  2001-07       Impact factor: 5.191

7.  Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD+, as a PARP inhibitor and by partial restoration of mitochondrial function.

Authors:  Lori Klaidman; Maria Morales; Seyha Kem; Jun Yang; Mei-Ling Chang; James D Adams
Journal:  Pharmacology       Date:  2003-11       Impact factor: 2.547

8.  Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes.

Authors:  Weihai Ying; Yongmei Chen; Conrad C Alano; Raymond A Swanson
Journal:  J Cereb Blood Flow Metab       Date:  2002-07       Impact factor: 6.200

9.  Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition.

Authors:  Conrad C Alano; Weihai Ying; Raymond A Swanson
Journal:  J Biol Chem       Date:  2004-02-11       Impact factor: 5.157

10.  Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model.

Authors:  Jun Yang; Lori K Klaidman; Mei Ling Chang; Seyha Kem; Taku Sugawara; Pak Chan; James D Adams
Journal:  Pharmacol Biochem Behav       Date:  2002-11       Impact factor: 3.533

View more
  17 in total

1.  Metabolic responses differentiate between interictal, ictal and persistent epileptiform activity in intact, immature hippocampus in vitro.

Authors:  Anton I Ivanov; Christophe Bernard; Dennis A Turner
Journal:  Neurobiol Dis       Date:  2014-12-19       Impact factor: 5.996

2.  Age- and AD-related redox state of NADH in subcellular compartments by fluorescence lifetime imaging microscopy.

Authors:  Yue Dong; Michelle A Digman; Gregory J Brewer
Journal:  Geroscience       Date:  2019-02-06       Impact factor: 7.713

Review 3.  Role of NAD+ and FAD in Ischemic Stroke Pathophysiology: An Epigenetic Nexus and Expanding Therapeutic Repertoire.

Authors:  Parimala Narne; Prakash Babu Phanithi
Journal:  Cell Mol Neurobiol       Date:  2022-09-30       Impact factor: 4.231

4.  Longitudinal in vivo tracking of adverse effects following topical steroid treatment.

Authors:  Andrew J Bower; Zane Arp; Youbo Zhao; Joanne Li; Eric J Chaney; Marina Marjanovic; Angela Hughes-Earle; Stephen A Boppart
Journal:  Exp Dermatol       Date:  2016-02-13       Impact factor: 3.960

5.  Nicotinamide improves sevoflurane-induced cognitive impairment through suppression of inflammation and anti-apoptosis in rat.

Authors:  Ying Wang; Min Zuo
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 6.  Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes.

Authors:  Nady Braidy; Jade Berg; James Clement; Fatemeh Khorshidi; Anne Poljak; Tharusha Jayasena; Ross Grant; Perminder Sachdev
Journal:  Antioxid Redox Signal       Date:  2018-05-11       Impact factor: 8.401

7.  Metabolic Profiles in Ovine Carotid Arteries with Developmental Maturation and Long-Term Hypoxia.

Authors:  Ravi Goyal; Lawrence D Longo
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

Review 8.  Contrasting Metabolic Insufficiency in Aging and Dementia.

Authors:  Dennis A Turner
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

Review 9.  Perinatal asphyxia: CNS development and deficits with delayed onset.

Authors:  Mario Herrera-Marschitz; Tanya Neira-Pena; Edgardo Rojas-Mancilla; Pablo Espina-Marchant; Daniela Esmar; Ronald Perez; Valentina Muñoz; Manuel Gutierrez-Hernandez; Benjamin Rivera; Nicola Simola; Diego Bustamante; Paola Morales; Peter J Gebicke-Haerter
Journal:  Front Neurosci       Date:  2014-03-26       Impact factor: 4.677

10.  Vestibular rehabilitation ameliorates chronic dizziness through the SIRT1 axis.

Authors:  Chung-Lan Kao; Kun-Ling Tsai; Yuan-Yang Cheng; Chia-Hua Kuo; Shin-Da Lee; Rai-Chi Chan
Journal:  Front Aging Neurosci       Date:  2014-03-04       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.